Mitarbeiter

Prof. Dr. med. Uwe Schlegel

1977 - 1979
Studium der Humanmedizin an der Universität Essen

1979 - 1983
Studium der Humanmedizin an der Freien Universität Berlin

1984
Promotion

1994
Habilitation
1984 - 1987
Wissenschaftlicher Assistent an der Neurologischen Universitätsklinik Bonn
1987 - 1988
Wissenschaftlicher Assistent an der Psychiatrischen Universitätsklinik Bonn
1989 - 1990
Ausbildungsstipendium der DFG und Tätigkeit als Research Fellow, Cotzias Laboratories of Neuro-Oncology, Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
1991 - 1992
Wissenschaftlicher Assistent (C1) an der Neurologischen Universitätsklinik Bonn
01. – 06.1993
Wissenschaftlicher Assistent an der Epileptologischen Universitätsklinik Bonn
07.1993
Oberarzt an der Neurologischen Universitätsklinik Bonn
12.1994
C2 Position an der Neurologischen Universitätsklinik Bonn
1999
Leitender Oberarzt der Neurologischen Universitätsklinik Bonn
Seit 12.2004
Direktor der Neurologischen Universitätsklinik am Knappschafts-Krankenhaus Bochum-Langendreer
1992
Bennigsen-Foerder Preis des Landes Nordrhein-Westfalen
2003
H.G. Mertens Preis der Deutschen Gesellschaft für Neurologie
  • Deutsche Gesellschaft für klinische Neurophysiologie und funktionelle Bildgebung
  • Deutsche Gesellschaft für Neurologie
  • Neuroonkologische Arbeitsgemeinschaft in der deutschen Krebsgesellschaft
  • European Association  for Neuro-Oncology (EANO)

Vorsitzender der Kommission Neuroonkologie innerhalb der Deutschen Gesellschaft für Neurologie

Vorsitzender der Kommission Psychosomatische Neurologie innerhalb der Deutschen Gesellschaft für Neurologie

Vorsitzender der Zertifizierungskommission – Neuroonkologische Zentren – innerhalb der Deutschen Krebsgesellschaft

Seit 1984 kontinuierlich universitäre Lehre der Neurologie in Vorlesung (seit 1993) und Praktikum (seit 1984)

Kebir S, Schaub C, Junold N, Hattingen E, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Galldilks N, Weller J, Mack F, Tzaridis T, Bähr O, Seidel C, Schlegel U, Schmidt-Graf F, Rohde V, Borchers C, Tabatabai G,  Hänel M, Sabel M, Gerlach R, Krex D, Belka C, Vatter H, Proescholdt M, Glas M, Herrlinger U. Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trail. J Neurooncol. 2019;[Epub  ahead of print]

Popkirov S, Schlegel U, Weber W, Kleffner I, Altenbernd J. Cardiac imaging within emergency CT angiography for acute stroke can detect atrial clots. Front Neurol. 2019;10: 349

Binder H, Willscher E, Loeffler-Wirth H, Hopp L, Jones DTW, Pfister SW, Kreuz M, Gramatzki D, Fortenbacher E, Hentschel B, Tatagiba M, Herrlinger U, Vatter H, Matschke J, Westpfahl M, Krex D, Schackert G, Tonn JC, Schlegel U, Steiger HJ, Wick W, Weber RG, Weller M, Loeffler M. DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development. Acta Neuropathol Commun. 2019;7: 59

Latzer P, Shchyglo O, Hartl T, Matschke U, Schlegel U, Manahan-Vaughan D, Theiss C. Blocking VEGF by bevacizumab compromises elektrohysiological and morphological properties of hippocampal neurons. Front Cell Neurosci. 2019;13: 113

Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyenbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M, Neurooncology Working Group of the German Cancer Society. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promotor (CeTeG/NOA 09): a randomised, open-label, phase 3 trial. Lancet 2019;393: 678 - 688

Schlegel U, Korfel A. Is whole-brain radiotherapy still a standard treatment for primary central nervous system lymphomas? Curr Opin Neurol. 2018;31: 733 - 739

von Baumgarten L, Illerhaus G, Korfel A, Schlegel U, Deckert M, Dreyling M. The diagnosis and treatment of Primary CNS Lymphoma. Dtsch. Ärzteblatt 2018;115: 419 - 426

Grönheit W, Popkirov S, Wehner T, Schlegel U, Wellmer J. Practical management of epileptic seizures and status epilepticus in adult palliative care patients. Front. Neurol. 2018;9:595. doi:10.3389/fneur.2018.00595

Schaub C, Kebir S, Junold N, Hattingen E, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Niessen M, Mack F, Stuplich M, Tzaridis T, Bähr O, Kortmann RD, Schlegel U, Schmidt-Graf F, Rohde V, Braun C, Hänel M, Sabel M, Gerlach R, Krex d, Belka C, Vatter H, Proeschold M, Herrlinger U, Glas M. Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trail. J Cancer Clin Oncol. 2018;144: 1581 - 1589

Schäfer N,  Proescholdt M, Steinbach JP, Weyerbrock A, Hau P, Grauer O, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Grau S, Hänel M, Schnell O, Krex D, Vajkoczy P, Tabatabai G, Mack F, Schaub C, Tzaridis T, Nießen M, Kebir S, Leutgeb B, Urbach H, Belka C, Stummer W, Glas M, Herrlinger U. Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. Neuro Oncol 2018;20: 975 - 985

Popkirov S, Jungilligens J, Schlegel U, Wellmer J. Research on dissociative seizure: A bibliometric analysis and visualization of the scientic landscape. Epilepsy Behav. 2018;83: 162 - 167

Popkirov S, Flasbeck V, Schlegel U, Juckel G, Brüne M. Alexithymia in borderline personality disorder is not asscociated with deficits in automatic visual processing of negative emotional stimuli. Psychiatry Res. 2018;263: 121 - 124

Popkirov S, Flasbeck V, Schlegel U, Juckel G, Brüne M. Childhood trauma and dissociative symptoms predict frontal EEG asymmetry in borderline personality disorder. J Trauma Dissociation 2018;15: 1 - 16

Baraniskin A, Chomiak M, Ahle G, Gress T, Buchholz M, Turewicz M, Eisenacher M, Margold M, Schlegel U, Schmiegel W, Hahn S, Schroers R. MicroRNA-30c as a novel diagnostic biomarker for primary and secondary B-cell lymphoma of the CNS. J Neurooncol. 2018;137: 463 - 468

Kowalski C, Graeven U, von Kalle C, Lang H, Beckmann MW, Blohmer JU, Burchardt M, Ehrenfeld M, Fichtner J, Grabbe S, Hoffmann H, Iro H, Post S, Scharl A, Schlegel U, Seufferlein T, Stummer W, Ukena D, Ferencz J, Wesselmann S. Shifting cancer care towards multidisciplinarity: the cancer center certification programm of the German cancer society. BMC Cancer 2017;850

Waldera-Lupa DM, Etemad-Parishanzadeh O, Brocksieper M, Kirchgaessler N, Seidel S, Kowalski T, Montesinos-Rongen M, Deckert M, Schlegel U, Stühler K. Proteomic changes in cerebrospinal fluid from primary central nervous system lymphoma patients are associated with protein ectodomain shedding. Oncotarget 2017;8

Dagmar D, Proescholt M, Reinert C, Pietsch T, Jones DTW, Pfister SM, Hattingen E, Seidel C, Dirven L, Luerding R, Reijneveld J, Warmuth-Metz M, Bonsanto M, Bremer M, Combs S, Rieken S, Herrlinger U, Kuntze H, Mayer-Steinacker R, Moskopp D, Schneider T, Beringer A, Schlegel U, Stummer W, Welker H, Weyerbrock A, Paulsen F, Rutkowski S, Weller M, Wick W, Kortmann RD, Bogdahn U, Hau P.  Multicenter pilot study of radio-chemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). Neuro Oncol. 2018;20: 400 - 410

Popkirov S, Ayzenberg I, Hahn S, Bauer J, Denno Y, Rieckhoff N, Radzimski C, Hans VH, Berg S, Roghmann F, Noldus J, Bien CG, Skodda S, Wellmer J, Stöcker W, Krogias C, Gold R, Schlegel U, Probst C, Komorowski L, Miske R, Kleiter I. Rho-associated protein kinase 2 (ROCK2): a new target of autoimmunity in paraneoplastic encephalitis. Acta Neuropathol. Commun 2017;5: 40 

Gramatzki D, Kickingereder P, Hentschel B, Felsberg J, Herrlinger U, Schackert G, Tonn JC, Westphal M, Sabel M, Schlegel U,Wick W, Pietsch T, Reifenberger G, Loeffler M, Bendszus M, Weller M. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma. Neurology 2017;88: 1422 - 1430

Kakkassery V, Schroers R, Coupland SE, Wunderlich MI, Schargus M, Heinz C, Wasmuth S, Heiligenhaus A, Ahle G, Lenoble P, Schlegel U, Schmiegel W, Dick HB, Baraniskin A. Vitre-ous microRNA levels as diagnostic biomarkers for vitreo-retinal lymphoma. Blood 2017;129: 3130 - 3133

lsmail SF, Schlegel U, Kowoll A, Skodda S. Episodic central hypopnea and hypotension: Caused by bleeding into a craniocervical ependymoma. Nervenarzt 2017;[Epub ahead of print]. 

lsmail FS, Enzi B, Boy C, Kowoll A, Eyding J, Schlegel U. Relapsing polychondritis as an unusual cause of multiple cranial nerve palsies - a case report. Muscle Nerve 2017;56:E3 - E4

Schlegel U, Korfel A. The challenge of adequate imaging surveillance in primary central nervous system lymphoma. Neuro Oncol. 2017;19: 307 - 308

Geisler T, Poli S, Meisner C, Schreieck J, Zuern CS, Nägele T, Brachmann J, Jung W, Gahn G, Schmid E, Bäezner H, Keller T, Petzold GC, Schrickel JW, Liman J, Wachter R, Schön F, Schabet M, Lindner A, Ludolph AC, Kimmig H, Jander S, Schlegel U, Gawaz M, Ziemann U. Apixaban for treatment of embolic strake of undetermined source (ATTICUS randomized trial): Rationale and study design. lnt J Stroke 2017;12: 985 - 990

Strehlow F, Bauer S, Martus P, Weller M, Roth P, Schlegel U, Seidel S, Scheibenbogen C, Korfel A, Kreher S. Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma. J Neurooncol 2016;126: 165 - 171 

Pitter KL, Tamagno I, Alikhanyan K, Hosni-Ahmed A, Pattwell SS, Donnala S, Dai C, Ozawa T, Chang M, Chan TA, Beal K, Bishop AJ, Baker CA, Jones TS, Hentschel B, Gorlia T, Schlegel U, Stupp R, Weller M, Holland EC, Hambardzumyan D. Corticosteroids compromi-se survival in glioblastoma. Brain 2016;139: 1458 - 1471 

Korfel A, Chamberlain M, Neuwelt E, Thiel E, Doolittle N, Schlegel U, Dreyling M, Rubenstein J, Fischer L, Björkholm M, Martus P, Weller M, Glantz M. Therapy for secondary CNS in-volvement in malignant lymphomas: No Standard yet! J Clin Oncol 2016;34: 1829 - 1830 

Korfel A, Schlegel U, Herrlinger U, Dreyerling M, Schmidt C, von Baumgarten L, Pezzutto A, Grobosch T, Kebir S, Thiel E, Martus P, Kiewe P. Phase II Trial of Temsirolimus for re-lapsed/refractory Primary CNS Lymphoma. J Clin Oncol. 2016;34: 1757 - 1763 

Latzer P, Schlegel U, Theiss C. Morphological changes of cortical and hippocampall Neurons after treatment with VEGF and Bevacizumab. CNS Neurosci Ther. 2016;22: 440 - 450 

Popkirov S, Schlegel U, Skodda S. ls postoperative encephalopathy with choreoathetosis an acquiered form of neurocanthocytosis? Med Hypotheses 2016;89: 21 - 23 

Herrlinger U, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Maciaczyk J, Grau S, Schnell O, Hänel M, Krex D, Vajkoczy P, Gerlach R, Kortmann RD, Mehdorn M, Tüttenberg J, Mayer-Steinacker R, Fietkau R, Brehmer S, Mack F, Stuplich M, Kebir S, Kohnen R, Dunkl E, Leutgeb B, Proescholdt M, Pietsch T, Urbach H, Belka C, Stummer W, Glas M. Bevacizumab plus lrinotecan versus Temozolomide in newly diagnosed 06-Methylguanine-DNA Methyltransferase nonmethylated Glioblastoma: The randomized GLARIUS Trail. J Clin Oncol. 2016;34: 1611 - 1619 

Popkirov S, Figge A, Schlegel U, Skodda S. Tertiary hyperparathyroidism presenting as pos-terior reversible encephalopathy syndrome. Neurology 2016;86: 695 - 696 

Suchorska B, Weller M, Tabatabai G, Senft C, Hau P, Sabel MC, Herrlinger U, Ketter R, Schlegel U, Marosi C, Reifenberger G, Wick W, Tann JC, Wirsching HG. Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR Trial. Neuro Oncol. 2016;18: 549 - 556 

Baraniskin A, Zaslava E, Nöpel-Dünnebacke S, Ahle G, Seidel S, Schlegel U, Schmiegel W, Hahn S, Schroers R. Circulating U2 small nuclear RNA fragments as a novel diagnostic bi-omarker for primary central nervous system lymphoma. Neuro Oncol. 2016,18: 361 - 367 

Suchorska B, Weller M, Tabatabai G, Senft C, Hau P, Sabel M, Herrlinger U, Ketter R, Schlegel U, Marosi C, Reifenberger G, Wick W, Tann JC, Wirsching HG. 136 Complete re-section of contrast­ enhancing tumor volume is associated with improved survival in recurrent glioblastoma results from the DIRECTOR Trail. Neurosurgery 2015;62 suppl 1:209 

Hoang-Xuan K, Bessell E, Bromberg J, Hottinger AF, Preusser M, Ruda R, Schlegel U, Siegal T, Soussain C, Abacioglu U, Cassoux N, Deckert M, Dirven CM, Ferreri AJ, Graus F, Henriksson R, Herrlinger U, Taphoorn M, Soffietti R, Weller M; European Association for Neuro-Oncology Task Force on Primary CNS Lymphoma. Diagnosis and treatment of prima-ry CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncol. 2015;16: e322 - 332 

Lang N, Esser W, Evers S, Kellinghaus C, Nguento A, Schlegel U, Gaida B, Gburek-Augustat J, Altenmüller DM, Burghaus L, Hoffmann F, Fiedler B, Bast T, Rehfeld T, Happe S, Seitz RJ, Boor R, Stephani U. lntravenous levetiracetam in clinical practise -Results from an independent registry. Seizure 2015;29: 109 - 113 

Korfel A, Schlegel U. Primary CNS lymphoma: Progress in the diagnostics and therapy. Nervenarzt 2015;86: 710 - 715 

Popkirov S, Kowalski T, Schlegel U, Skodda S. lmmunoglobulin-G4-related hypertrophic pachymeningitis with antineutrophil cytoplasmatic antibodies effectively treated with rituxi-mab. J Clin Neurosci. 2015;22: 1038 - 1040 

Weller M, Weber RG, Willscher E, Riehmer V, Hentschel B, Kreuz M, Felsberg J, Beyer U, Löffler-Wirth H, Kaulich K, Steinbach JP, Hartmann C, Gramatzki D, Schramm J, Westphal M, Schackert G, Simon M, Martens T, Boström J, Hagel C, Sabel M, Krex D, Tann JC, Wick W, Noell S, Schlegel U, Radlwimmer B, Pietsch T, Loeffler M, von Deimling A, Binder H. Reifenberger G. Molecular classification of diffuse cerebral WHO grade 11/111 gliomas using genome-and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol. 2015;129: 679 - 693

Korfel A, Schlegel U, Schroers R. Special hematological diagnostics and therapy options for ocular lymphoma taking CNS involvement into account. Ophtalmologe 2015;112: 231 - 236 

Weller M, Tabatabai G, Kästner B, Felsberg J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabel MC, Wirsching HG, Ketter R, Bähr O, Platten M, Tonn JC, Schlegel U, Marosi C, Goldbrunner R, Stupp R, Homicsko K, Pichler J, Nikkah G, Meixensberger J, Vajkoczy P, Kollias S, Hüsing J, Reifenberger G, Wick W. MGMT promotor methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial. Clin Cancer Res. 2015;21: 2057 - 2064

Westphal M, Heese O, Steinbach JP, Schnell O, Schackert G, Mehdorn M, Schulz D, Simon M, Schlegel U, Senft C, Geletneky K, Braun C, Hartung JG, Reuter D, Metz MW, Bach F, Pietsch T. A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glio-blastoma. Eur J Cancer 2015;51: 522 - 532

Rusz J, Saft C, Schlegel U, Hoffmann R, Skodda S. Phonatory dysfunction as a preclinical symptom of Huntington disease. PloS One 2014;9(11): el13412 

Tabatabai G, Hattingen E, Schlegel J, Stummer W, Schlegel U. lnterdisciplinary neuro-oncology: Part 2: systemic therapy of primary brain tumors. Nervenarzt 2014;85: 976 - 981 

Tabatabai G, Hattingen E, Schlegel J, Stummer W, Schlegel U. lnterdisciplinary neuro-oncology Part 1: diagnostics and operative therapy of primary brain tumors. Nervenarzt 2014;85: 965 - 975 

Popkirov S, Grönheit W, Schlegel U, Wellmer J. Recurrent loss of consciousness despite DDD pacing: psychogenic pseudosyncope in a 19-year-old man. Clin Res Cardiol. 2014; 103: 755 - 757 

Reifenberger G, Weber RG, Riehmer V, Kaulich K, Willscher E, Wirth H, Gietzelt J, Hentschel B, Westphal M, Simon M, Schackert G, Schramm J, Matschke J, Sabel MC, Gramatzki D, Felsberg J, Hartmann C, Steinbach JP, Schlegel U, Wick W, Radlwimmer B, Pietsch T, Tonn JC, von Deimling A, Binder H, Weller M, Loeffler M; for the German Glioma Network. Molecular characterization of long­term survivors of glioblastoma using genome-and transcriptome-wide profiling. lnt J Cancer 2014;135: 1822 - 1831 

Skodda S, Schlegel U, Hoffmann R, Saft C. lmpaired motor speech performance in Huntington's disease. J Neurol Transm. 2014;121: 399 - 407 

Eisele G, Wick A, Eisele AC, Clement PM, Tonn J, Tabatabai G, Ochsenbein A, Schlegel U, Neyns B, Krex D, Simon M, Nikkhah G, Picard M, Stupp R, Wick W, Weller M. Cilengitide treatment of newly diagnoses glioblastoma patients does not alter patterns of progression. J Neurooncol 2014;117: 141 - 145 

Skodda S, Grönheit W, Schlegel U, Südmeyer M, Schnitzler A, Wojtecki L. Effect of sub-thalmatic Stimulation on voice and speech in Parkinson's disease: for the better or worse? Front Neurol. 2014;4: 218 

Heese O, Vogeler E, Martens T, Schnell O, Tonn JC, Simon M, Schramm J, Krex D, Schackert G, Reithmeier T, Nikkah G, Sabe M, Steiger HJ, Schlegel U, Löffler M, Weller M, Westphal M; for the German Glioma Network. End-of-life caregivers'perception of medical and psychological support during the final weeks of glioma patients: a questionnaire-based survey. Neuro Oncol. 2013;15: 1251 - 1256

Doolittle ND, Korfel A, Lubow MA, Schorb E, Schlegel U, Rogowski S, Fu R, Dósa E, lllerhaus G, Kraemer DF, Muldoon LL, Calabrese P, Hedrick N, Tyson RM, Jahnke K, Maron LM, Butler RW, Neuwelt EA. Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma. Neurology 2013;81: 84 - 92 

Korfel A, Schlegel U. Diagnosis and treatment of primary CNS lymphoma. Nat Rev Neural. 2013;9: 317 - 327

Semmler A, Garbe S, Moskau S, Fisch C, Eter N, Schlegel U, Linnebank M. An efficient method for fractionated whole rodent brain radiation. Neural Res. 2013;35: 355 - 359

Korfel A, Elter T, Thiel E, Hänel M, Möhle R, Schroers R, Reiser M, Dreyling M, Eucker J, Scholz CW, Metzner B, Röth A, Birkmann J, Schlegel U, Martus P, lllerhaus G, Fischer L. Phase II study of CNS­directed chemotherapy uncluding high-dose chemotherapy with auto-logous stem cell transplantation for CNS relapse of aggressive lymphomas. Haematologica 2013;98: 364 - 370 

Eyding J, Grönheit W, Rother S, Skodda S, Heuser L, Alekseyev A, Schlegel U. Optimised rate of specific, revascularising therapies in acute stroke-what is the aim? Considerations from the experience of a tertiary center. Fortschr Neurol -Psychiat. 2013;81: 69 - 74 

Linnebank M, Moskau S, Kowoll A, Semmler A, Bangard C, Vogt-Schaden M, Egerer G, Schackert G, Reichmann H, Schmidt-Wolf IG, Pels H, Schlegel U. Association of trans-cobalamin c. 776>G with overall survival in patients with primary central nervous system lymphoma. Br J Cancer. 2012;107: 1840 - 1843 

Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixenberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M; NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society. Pels H, Schlegel U, Herrlinger U, Pietsch T, Schramm J, Krex D, Schackert G, Rapp M, Wille C, Blümcke I, Diener HC, Bähr O, Rieger J, Franz K, Seifer V, Plate KH, Wille C, Westphal M, Heidenreich F, Wiese B, Bremer M, Nakamura M, v Deimling A, Klein AC, Pfennig P, Schemmer D, Wick A, Oertel J, Kortmann R, Conrad J, Wiewrodt D, Sehmieder K, Wenz F, Bogdahn U, Hau P, Bamberg M, Melms A, Döhner H, Happold C, Zaugg K. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13: 707 - 715

Kuhnhenn J, Kowalski T, Steenken S, Ostermann K, Schlegel U. Procarbazine, carmustine and vincristine (PBV) for chemotherapy pre-treated patients with recurrent glioblastoma: a single­institution analysis. J Neurooncol. 2012;109: 433 - 438 

Baraniskin A, Kuhnhenn J, Schlegel U, Schmiegel W, Hahn S, Schroers R. MicroRNAs in cerebrospinal fluid as biomarker for disease course monitoring in primary central nervous system lymphoma. J Neurooncol. 2012;109: 239 - 244 

Skodda S, Grönheit W, Schlegel U. lmpairment of vowel articulation as a possible marker of disease progression in Parkinson's disease. PloS ONE 2012; 7(2): e32132 

Eyding J, Wiebringhaus R, Klein FG, Skodda S, Schlegel U, Alekseyez A, Heuser L. Multi-modal CT imaging and recanalizing therapy in acute ischemic strake - retrospective analysis of a one year single centre experience. Eur Neurol. 2012;67: 193 - 199 

Sczesni KC, Alekseyev A, Schlegel U, Skodda S. [Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids]. Nervenarzt 2012;83: 775 - 781 

Schmitz-Hübsch T, Eckert O, Schlegel U, Klockgether T, Skodda S. lnstability of syllable repetition in patients with spinocerebellar ataxia and Parkinson's disease. Mov Disord. 2012; 27: 316 - 319

Baraniskin A, Deckert M, Schulte-Altedorneburg G, Schlegel U, Schroers R. Current strate-gies in the diagnosis of diffuse large B-cell lymphoma of the central nervous system. Br J Haematol. 2012;156: 421 - 432

Baraniskin A, Kuhnhenn J, Schlegel U, Maghnouj A, Zöllner H, Schmiegel W, Hahn S, Schroers R. ldentification of microRNAs in the cerebrospinal fluid as biomarker for the diag-nosis of glioma. Neuro Oncol. 2012;14: 29 - 33 

Flasskamp A, Kotz SA, Schlegel U, Skodda S. Acceleration of syllable repetition in Parkin-son's disease is more prominent in the left-side dominant patients. Parkinsonism Relat Disord. 2012;18: 343 - 347 

Skodda S, Grönheit W, Schlegel U. lnstability of syllable repetition in progressive supranu-clear palsy. J Neural Transm. 2012;119: 457 - 462 

Steinbeck JA, Stuplich M, Blasius E, Pels H, Glas M, Schlegel U, Herrlinger U. Relapse of primary central nervous system lymphoma 13 years after high-dose methotrexate-based polychemotherapy. J Clin Neurosci. 2011;18: 1554 - 1555 

Deckert M, Engert A, Brück W, Ferreri AJ, Finke J, lllerhaus G, Klapper W, Korfel A, Küppers R,  Maarouf M, Montesinos-Rongen M, Paulus W, Schlegel U, Lassmann H, Wiestler O, Siebert R,  Deangelis LM. Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. Leukemia. 2011;25: 1797 - 1807 

Patrij K, Reiser M, Wätzel L, Pels H, Kowoll A, Herrlinger U, Engert A, Linnebank M, Schackert G, Vogt-­Schaden M, Egerer G, Lamprecht M, Batchelor TT, Schlegel U, Schmidt-Wolf IG. International Primary CNS Lymphoma Collaborative Group (IPCG). lsolated central nervous system relapse of systemic  lymphoma (SCNSL): clinical features and outcome of a retrospective analysis. Ger Med Sei. 2011;9: Docll 

Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox KM, Hennerici MG, Mattle HP, Rothwell PM, de Cordoüe A, Fratacci MD; PERFORM Study lnvestigators. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM); a randomised, double-blind, parallel-group trial. Lancet 2011;377: 2013 - 2022 

Skodda S, Visser W, Schlegel U. Gender-related patterns of dysprosody in Parkinson dis-ease and correlation between speech variables and motor symptoms. J Voice. 2011;25: 76 - 82 

Baraniskin A, Kuhnhenn J, Schlegel U, Chan A, Deckert M, Gold R, Maghnouj A, Zöllner H, Reinacher-­Schick A, Schmiegel W, Hahn SA, Schroers R. ldentification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood. 2011;117: 3140 - 3146 

Hinkerohe D, Wolfkühler D, Haghikia A, Meier C, Faustmann PM, Schlegel U. Dexame-thasone differentially regulates functional membrane properties in glioma cell lines and pri-mary astrocytes in vitro. J Neurooncol. 2011;103: 479 - 489 

Skodda S, Flasskamp A, Schlegel U. lnstability of syllable repetition in Parkinson's disease-influence of levodopa and deep brain stimulation. Mov Disord. 2011;26: 728 - 730 

Skodda S, Grönheit W, Schlegel U. Intonation and speech rate in Parkinson's disease: gen-eral and dynamic aspects and responsiveness to levodopa admission. J Voice. 2011;25: 199 - 205

Ostermann K, Pels H, Kowoll A, Kuhnhenn J, Schlegel U. Neurologie complications after intrathecal liposomal cytarabine in combination with systemic polychemotherapy in primary CNS lymphoma. J Neurooncol. 2011;103: 635 - 640 

Skodda S, Flasskamp A, Schlegel U. lnstability of syllable repetition as a marker of disease progression in Parkinson's disease: a longitudinal study. Mov Disord. 2011;26: 59 - 64 

Fischer L, Koch A, Schlegel U, Koch HC, Wenzel R, Schröder N, Thiel E, Korfel A. Non-enhancing relapse of a primary CNS lymphoma with multiple diffusion-restricted lesions. J Neurooncol. 2011;102: 163 - 166 

Skodda S, Visser W, Schlegel U. Acoustical analysis of speech in progressive supranuclear palsy. J Voice. 2011;25: 725 - 731 

Skodda S, Visser W, Schlegel U. Vowel articulation in Parkinson's disease. J Voice. 2011;25: 467 - 472 

Schroers R, Baraniskin A, Heute C, Vorgerd M, Brunn A, Kuhnhenn J, Kowoll A, Alekseyev A, Schmiegel W, Schlegel U, Deckert M, Pels H. Diagnosis of leptomeningeal disease in diffuse large B­cell lymphomas of the central nervous system by flow cytometry and cyto-pathology. Eur J Haematol. 2010;85: 520 - 528 

Schroers R, Baraniskin A, Heute C, Kuhnhenn J, Alekseyev A, Schmiegel W, Schlegel U, Pels HJ. Detection of free immunoglobulin light chains in cerebrospinal fluids of patients with central nervous system lymphomas. Eur J Haematol. 2010;85: 236 - 242 

Fliessbach K, Rogowski S, Hoppe C, Sabel M, Goeppert M, Helmstaedter C, Calabrese P, Schackert G, Tann JC, Simon M, Schlegel U. Computer-based assessment of cognitive functions in brain tumor patients. J Neurooncol. 2010;100: 427 - 437

Stupp R, Hegi M, Neyns B, Goldbrunner R, Schlegel U, Clement P, Grabenbauer G, Ochsenbein A, Simon M, Dietrich P, Pietsch T, Hicking C, Tann J, Diserens A, Pica A, Hermisson M, Krueger S, Picard M, Weller M. Phasel/lla study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28: 2712 - 2718 

Skodda S, Flasskamp A, Schlegel U. lnstability of syllable repetition as a model for impaired motor processing: is Parkinson's disease a "rhythm disorder"? J Neural Transm. 2010;117: 605 - 612 

Hinkerohe D, Smikalla D, Schoebel A, Haghikia A, Zoidl G, Haase CG, Schlegel U, Faust-mann PM. Dexamethasone prevents LPS-induced microglial activation and astroglial im-pairment in an experimental bacterial meningitis co-culture model. Brain Res. 2010; 1329: 45 - 54 

Juergens A, Pels H, Rogowski S, Fliessbach K, Glasmacher A, Engert A, Reiser M, Diehl V, Vogt-­Schaden M, Egerer G, Schackert G, Reichmann H, Kroschinsky F, Bode U, Herrlinger U, Linnebank M, Deckert M, Fimmers R, Schmidt-Wolf IG, Schlegel U. Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lym-phoma. Ann Neural. 2010;67: 182 - 189 

Grzendowski M, Walter M, Riemenschneider MJ, Knobbe CB, Schlegel U, Meyer HE, Reifenberger G, Stühler K. Differential proteome analysis of human gliomas stratified for lass of heterozygosity on chromosomal arms lp and 19q. Neuro Oncol. 2010;12: 243 - 256 

Pels H, Juergens A, Schirgens I, Glasmacher A, Schulz H, Engert A, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Deckert M, Fimmers R, Urbach H, Schmidt-Wolf IG, Schlegel U. Early complete response during chemotherapy predicts favorable outcome in patients with primary CNS lymphoma. Neuro Oncol. 2010;12: 720 - 724

Skodda S, Visser W, Schlegel U. Short- and long-term dopaminergic effects on dysarthria in early Parkinson's disease. J Neural Transm. 2010;117:197 - 205

  • Klinische Therapiestudien bei primären Gehirntumoren
  •  Biologische Veränderungen im Hirntumorgewebe und ihre prognostische Bedeutung
  •  Therapie-assoziierte Neurotoxizität
  • Diagnostik und Therapie primärer ZNS Lymphome
Anfahrt
Neurologische Klinik

Universitätsklinikum
Knappschaftskrankenhaus
Bochum GmbH

Anschrift

In der Schornau 23–25
44892 Bochum

Kontakt
Telefon
0234 299–3701
Telefax
0234 299–3719
E-Mail
neurologie@kk-bochum.de